219 related articles for article (PubMed ID: 28104527)
21. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
23. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
25. TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using
Minnix M; Li L; Yazaki PJ; Miller AD; Chea J; Poku E; Liu A; Wong JYC; Rockne RC; Colcher D; Shively JE
J Nucl Med; 2021 Jan; 62(1):55-61. PubMed ID: 32620701
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R).
Geller DS; Morris J; Revskaya E; Kahn M; Zhang W; Piperdi S; Park A; Koirala P; Guzik H; Hall C; Hoang B; Yang R; Roth M; Gill J; Gorlick R; Dadachova E
Nucl Med Biol; 2016 Dec; 43(12):812-817. PubMed ID: 27744117
[TBL] [Abstract][Full Text] [Related]
27. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
28. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
29. Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis.
Park BN; Lee SJ; Roh JH; Lee KH; An YS; Yoon JK
Mol Imaging; 2017; 16():1536012117737399. PubMed ID: 29239276
[TBL] [Abstract][Full Text] [Related]
30. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.
Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW
Cancer Biother Radiopharm; 2005 Oct; 20(5):557-68. PubMed ID: 16248771
[TBL] [Abstract][Full Text] [Related]
31. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
32. Molecular imaging of T cell co-regulator factor B7-H3 with
Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
34. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.
Meredith RF; Torgue JJ; Rozgaja TA; Banaga EP; Bunch PW; Alvarez RD; Straughn JM; Dobelbower MC; Lowy AM
Am J Clin Oncol; 2018 Jul; 41(7):716-721. PubMed ID: 27906723
[TBL] [Abstract][Full Text] [Related]
35. Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models.
Metebi A; Kauffman N; Xu L; Singh SK; Nayback C; Fan J; Johnson N; Diemer J; Grimm T; Zamiara M; Zinn KR
Front Chem; 2023; 11():1322773. PubMed ID: 38333550
[No Abstract] [Full Text] [Related]
36. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
[TBL] [Abstract][Full Text] [Related]
37. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
38. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
39. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
40. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
